New study finds promising drug doubled positive effect in hormone-receptor positive breast cancer — ScienceDaily

An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in progression-free survival (PFS0 for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment letrozole and palbociclib, compared to letrozole alone. …

New study finds promising drug doubled positive effect in hormone-receptor positive breast cancer

An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in progression-free survival (PFS0 for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment letrozole and palbociclib, compared to letrozole alone. “We’re essentially putting the brakes on cell proliferation and causing these tumor cells to stop growing,” said Dr. Richard Finn, associate professor of medicine at UCLA and lead author of the study…

FDA approval of nonavalent HPV vaccine adds new tool to eradicate cervical cancer

It is estimated that the seven “high-risk” HPV types found in the nonavalent vaccine can potentially prevent over 90 percent of cervical cancers and a similarly high number of other HPV-associated cancers of the vulva, vagina, anus, penis, and some head and neck cancers. “As the healthcare providers for women who suffer from cervical and lower genital tract cancers, members of the SGO have always been advocates for the primary prevention of cervical and other HPV-related cancers,” said SGO President Richard R…

Islet cell transplantation after pancreas removal may help preserve normal blood sugar

Chronic pancreatitis (CP) is an inflammatory disease that over time leads to loss of function of the pancreas and manifests with intractable pain, malabsorption and diabetes. While medical management and pain control are the initial approaches to CP, some patients need to undergo more invasive procedures to relieve ductal pressure in the pancreas. If those measures fail, surgical options can include total removal of the pancreas (total pancreatectomy, TP) or the Whipple procedure to remove part of the pancreas. Total pancreas removal produces diabetes because insulin-secreting cells are removed…

To sleep, perchance to dream of a cure

And once the sleep was lost, there was no getting its positive effect back by allowing extra rest later. In “Recovery Sleep Does Not Mitigate the Effects of Prior Sleep Loss on Paclitaxel-Induced Mechanical Hypersensitivity in Sprague-Dawley Rats,” a preclinical study published in Biological Research for Nursing, restricted sleep among rats led to worse reactions to PAC, associated with painful, debilitating peripheral neuropathy of the hands and feet that may persist long after therapy is completed. According to the study, “How poor sleep sets the stage for adverse outcomes among people diagnosed with cancer is not entirely understood…

Promising drug doubled positive effect in hormone-receptor positive breast cancer, study finds

An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in PFS for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment, letrozole, and palbociclib compared to letrozole alone. “We’re essentially putting the brakes on cell proliferation and causing these tumor cells to stop growing,” said Dr. …

GPs should be more open when referring patients for cancer investigations, study says

They found that patients were rarely involved in the decision to be referred for investigation and that reasons for referral tended to be couched in non-specific terms rather than ‘cancer investigation’, even when the patient was on a cancer-specific pathway. The National Institute for Health and Care Excellence (NICE) referral guidelines emphasise that the patient should be involved in the decision-making process and be informed of the reasons for referral…